Featured Research

from universities, journals, and other organizations

30 Percent RA Patients Refractory To Anti-TNFs Achieve Disease Remission With Tocilizumab Plus Metho

Date:
June 13, 2008
Source:
European League Against Rheumatism
Summary:
Tocilizumab plus methotrexate showed significant clinical improvements in efficacy and safety in patients with moderate to severe rheumatoid arthritis, who had not adequately responded to anti-tumour necrosis factor (anti-TNF) therapy. Tocilizumab, an anti-interleukin (IL)-6 receptor monoclonal antibody, was demonstrated to be effective irrespective of the number of, or the most recently-failed anti-TNF treatments.

Tocilizumab plus methotrexate showed significant clinical improvements in efficacy and safety in patients with moderate to severe rheumatoid arthritis (RA), who had not adequately responded to anti-tumour necrosis factor (anti-TNF) therapy, according to a new study presented June 13 at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France. Tocilizumab, an anti-interleukin (IL)-6 receptor monoclonal antibody, was demonstrated to be effective irrespective of the number of, or the most recently-failed anti-TNF treatments.

Related Articles


After 24 weeks of treatment, 30.1% (p<0.0001) of patients receiving 8mg/kg tocilizumab plus methotrexate, who had active RA despite prior anti-TNF therapy, achieved DAS28 (a measure of disease remission) compared with only 1.6% in the placebo arm. 50% (p<0.0001) of patients on the same regime achieved the study's primary endpoint of ACR20 (a 20% improvement in symptoms) compared to 10% of patients in the placebo arm. Patients receiving 4mg/kg tocilizumab plus methotrexate experienced similar, though slightly lower results with 7.6% (p=0.0533) achieving DAS28 and 30.4% (p<0.0001) achieving ACR20.

Professor Paul Emery of Leeds Teaching Hospital Trust / Leeds University, UK, lead investigator in the trial, said: "Although anti-TNF therapies for RA are well-established, a substantial number of patients are inadequately controlled by these treatments, or become refractory to them. The results of this trial suggest that tocilizumab offers a much needed and effective option for such patients."

The RADIATE study was a randomised, double-blind study of 499 patients with moderate to severe RA. 12-18% of patients had 3 or more prior anti-TNF failures. A low proportion of the patients in the 8mg/kg tocilizumab group experienced serious adverse effects (6%) or serious infections (5%) during the trial. There was no difference in safety or tolerability based on prior anti-TNF treatment.


Story Source:

The above story is based on materials provided by European League Against Rheumatism. Note: Materials may be edited for content and length.


Cite This Page:

European League Against Rheumatism. "30 Percent RA Patients Refractory To Anti-TNFs Achieve Disease Remission With Tocilizumab Plus Metho." ScienceDaily. ScienceDaily, 13 June 2008. <www.sciencedaily.com/releases/2008/06/080613133038.htm>.
European League Against Rheumatism. (2008, June 13). 30 Percent RA Patients Refractory To Anti-TNFs Achieve Disease Remission With Tocilizumab Plus Metho. ScienceDaily. Retrieved November 23, 2014 from www.sciencedaily.com/releases/2008/06/080613133038.htm
European League Against Rheumatism. "30 Percent RA Patients Refractory To Anti-TNFs Achieve Disease Remission With Tocilizumab Plus Metho." ScienceDaily. www.sciencedaily.com/releases/2008/06/080613133038.htm (accessed November 23, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, November 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com
Could Your Genes Be The Reason You're Single?

Could Your Genes Be The Reason You're Single?

Newsy (Nov. 21, 2014) Researchers in Beijing discovered a gene called 5-HTA1, and carriers are reportedly 20 percent more likely to be single. Video provided by Newsy
Powered by NewsLook.com
Raw: Paralyzed Marine Walks With Robotic Braces

Raw: Paralyzed Marine Walks With Robotic Braces

AP (Nov. 21, 2014) Marine Corps officials say a special operations officer left paralyzed by a sniper's bullet in Afghanistan walked using robotic leg braces in a ceremony to award him a Bronze Star. (Nov. 21) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins